Life Sciences

INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial
21 April 2022

INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial

MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to...

Read the press release
BCD Bioscience, a Precision Prebiotic Fiber Company, Raises $12M In Series A Funding to Develop Lead Products
13 April 2022

BCD Bioscience, a Precision Prebiotic Fiber Company, Raises $12M In Series A Funding to Develop Lead Products

BCD Bioscience, a biotechnology company creating precision prebiotics from natural fibers, today announced that it has completed an oversubscribed Series A financing round of...

Read more
MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease
28 March 2022

MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease

A French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer,...

Read the press release
Microbiome Space in Spotlight as Microbiotica Sets Funding Record
11 March 2022

Microbiome Space in Spotlight as Microbiotica Sets Funding Record

Competition is heating up in the microbiome niche as UK-based Microbiotica raised €60M (£50M) in a Series B round to advance two candidates designed to treat cancer and...

Read more
Backing the Microbiome: The Investor Perspective
11 March 2022

Backing the Microbiome: The Investor Perspective

Life science research changes frequently, with new discoveries being published every day. Some of these discoveries form the basis of new biotech companies, but whether or not...

Read more
Microbiotica raises £50 million ($67 million) to advance pipeline of microbiome-based therapeutics
7 March 2022

Microbiotica raises £50 million ($67 million) to advance pipeline of microbiome-based therapeutics

Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series...

Read the press release
OIA launches project to produce alternative protein from dates
20 February 2022

OIA launches project to produce alternative protein from dates

Focusing on its role in attracting foreign investments and advanced technologies to the sultanate, Oman Investment Authority (OIA) has signed an agreement with US-based...

Read more
Maat Pharma and Skyepharma have entered a partnership to establish the first exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France
14 February 2022

Maat Pharma and Skyepharma have entered a partnership to establish the first exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France

MaaT Pharma (EURONEXT: MAAT), a French clinical-stage biotech (Phase 3) and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival...

Read the press release